GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.

The stock's fall snapped an eight-day winning streak.

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is ...

Pacira BioSciences PCRX announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects ...

University of Colorado professor Leslie Leinwand thinks studying python hearts could lead to treatments for human heart disease ...

Timely remdesivir treatment in immunocompromised patients infected with COVID-19 is associated with improved survival outcomes.

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...